Disrupting resistance to EGFR-specific tyrosine kinase inhibitors in TP53-mutated lung carcinoma cell lines by proteasome inhibition

被引：0
|
作者：
Orth, Franziska
Schaefer, Benjamin
Harsch, Annika
Weller, Sandra
Beigl, Tobias
Barber, Lynn
Kopp, Hans-Georg
Essmann, Frank
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-2532
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2532
引用
收藏
页数：2
相关论文
共 50 条
  • [31] EGFR and p53 Status of Pulmonary Pleomorphic Carcinoma: Implications for EGFR Tyrosine Kinase Inhibitors Therapy of an Aggressive Lung Malignancy
    Yih-Leong Chang
    Chen-Tu Wu
    Jin-Yuan Shih
    Yung-Chie Lee
    Annals of Surgical Oncology, 2011, 18 : 2952 - 2960
  • [32] EGFR and p53 Status of Pulmonary Pleomorphic Carcinoma: Implications for EGFR Tyrosine Kinase Inhibitors Therapy of an Aggressive Lung Malignancy
    Chang, Yih-Leong
    Wu, Chen-Tu
    Shih, Jin-Yuan
    Lee, Yung-Chie
    ANNALS OF SURGICAL ONCOLOGY, 2011, 18 (10) : 2952 - 2960
  • [33] Characterization of mouse hepatocellular carcinoma cell lines to understand resistance to tyrosine kinase inhibitors.
    Zhou, Shuang
    Abe, Yuichi
    Kajino, Taisuke
    Isomura, Hisanori
    Yamaguchi, Rui
    Ishigami, Masatoshi
    Fujishiro, Mitsuhiro
    Taguchi, Ayumu
    CANCER SCIENCE, 2024, 115 : 1909 - 1909
  • [34] Mechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer
    Krawczyk, Pawel
    Mlak, Radoslaw
    Powrozek, Tomasz
    Nicos, Marcin
    Kowalski, Dariusz M.
    Wojas-Krawczyk, Kamila
    Milanowski, Janusz
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2012, 16 (05): : 401 - 406
  • [35] Radiographic Appearance of Leptomeningeal Disease in Patients with EGFR Mutated Non-Small Cell Lung Carcinoma Treated with Tyrosine Kinase Inhibitors - A Case Series
    Sener, Ugur
    Lin, Andrew
    Yang, Jonathan
    Malani, Rachna
    NEUROLOGY, 2019, 92 (15)
  • [36] Linker-phosphorylated SMAD2 induces resistance to tyrosine kinase inhibition in EGFR-mutated lung adenocarcinoma
    Eunjin, Bae
    Yoon, Jeonghwan
    Makino, Yojiro
    Tamura, Atsumi
    Lee, Inkyu
    Han, Jinsoo
    Ju, Jihyun
    Sukeda, Aoi
    Nagao, Toshitaka
    Ohira, Tatsuo
    Ikeda, Norihiko
    Miyazawa, Keiji
    Kato, Mitsuyasu
    Kuroda, Masahiko
    Mamura, Mizuko
    CANCER SCIENCE, 2022, 113 : 1001 - 1001
  • [37] PTK6 inhibition potentiates the effects of the EGFR antibody cetuximab and the small tyrosine kinase inhibitors on pancreatic carcinoma cell lines proliferation
    Saceda, M.
    Fernandez-Ballester, G.
    Encinar-Hidalgo, J. A.
    Caruana, P.
    Poveda-Delltel, M.
    Lucero-Calabuig, P.
    Garcia-Morales, P.
    Martinez-Lacaci, I.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S16 - S17
  • [38] Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
    Wang, Jun
    Wang, Baocheng
    Chu, Huili
    Yao, Yunfeng
    ONCOTARGETS AND THERAPY, 2016, 9 : 3711 - 3726
  • [39] Management of leptomeningeal metastases in EGFR mutated non-small cell lung cancer: Analysis of tyrosine kinase inhibitors sequence
    Flippot, R.
    Auclin, E.
    Biondani, P.
    Le Rhun, E.
    Adam, J.
    Planchard, D.
    Caramella, C.
    Le Pechoux, C.
    Lacroix, L.
    Gazzah, A.
    Mezquita, L.
    Besse, B.
    ANNALS OF ONCOLOGY, 2018, 29 : 523 - 523
  • [40] Research Trends of Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer: A Bibliometric Analysis
    Chang, Xiaoyan
    Wang, Chenghao
    Zhang, Linyou
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2025, 19 : 1703 - 1719
12345